Status:
COMPLETED
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Prostate Cancer
Osteoporosis
Eligibility:
MALE
Brief Summary
Osteoporosis, or thinning of the bones is a common disorder which can cause significant morbidity in terms of pain and fracture. One of the causes of osteoporosis is a low or absent testosterone level...
Detailed Description
INTRODUCTION - Osteoporosis is a common disorder with many predisposing factors including hypogonadism from a variety of causes. Prostate cancer is the second most common malignancy in men. The standa...
Eligibility Criteria
Inclusion
- Prostate cancer patients, on hormone therapy
Exclusion
- No prostate cancer
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00124410
Start Date
January 1 2000
Last Update
February 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2